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Abstract 
Background: Myeloperoxidase (MPO) is a lysosomal hemoprotein found in the azurophilic granules in neutrophils. 
Myeloperoxidase plays an important role in oxygen-dependent killing of bacteria, fungi, virus and malignant cells. 
Diabetes mellitus (DM) is listed among conditions that may lead to secondary MPO deficiency in neutrophils but 
inconsistent results concerning MPO activity in diabetic patients have been reported in the literature. In this study, we 
aimed to evaluate the relationship between glycemic control in patients with type 2 DM and MPO activity in neutro-
phils from a histochemical perspective.
Methods: The study included 40 patients with type 2 DM with poor glycemic control, 30 patients with type 2 DM 
with good glycemic control and 31 healthy controls. Peripheral blood smears were analyzed for each patient included 
in the study. Myeloperoxidase dye was used for staining. Myeloperoxidase ratios in neutrophil were evaluated for 
proportions of staining with MPO in 100 neutrophils in each smear. SPSS 16.0 version was used for statistical analyses.
Results: Myeloperoxidase ratios in neutrophils were 70 (58.5–80) in type 2 DM patients with poor glycemic control 
compared to 80 (73.75–90) in those with good glycemic control and 88 (78–92) in healthy controls. The DM group 
with poor glycemic control was statistically significantly different from the other groups (p < 0.001).
Conclusions: Poor glycemic control in diabetic patients results in decreased MPO activity in neutrophils 
histochemically.
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Background
Several microbicidal dysfunctions of the neutrophils and 
monocytes have been defined as a factor that contrib-
utes to complications and to morbidity and mortality in 
diabetic patients [1, 2]. Deficiencies in a number of func-
tions have been demonstrated in the neutrophils of dia-
betic patients [3–5]. Oxidative stress and reactive oxygen 
species are known to have important roles in the etiol-
ogy of diabetes, in development of its complications and 
in disease progression [6]. Myeloperoxidase (MPO) is a 
lysosomal hemoprotein found in the azurophilic gran-
ules in neutrophils [7]. It is a potent bactericidal enzyme 
that produces reactive oxygen species. Myeloperoxidase 
plays an important role in oxygen-dependent killing of 
bacteria, fungi, virus and malignant cells. Myeloperoxi-
dase-mediated damage is not limited to intraphagosomal 
microbes. It is involved in the pathogenesis of several 
inflammatory conditions, atherosclerosis, demyelinating 
diseases of the central nervous system and some tumors 
[8–10].
Diabetes mellitus (DM) is listed among conditions that 
may lead to secondary MPO deficiency in neutrophils [9] 
but inconsistent results concerning MPO activity in dia-
betic patients have been reported in the literature [11–
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glycemic control in diabetic patients on MPO activity in 
neutrophils has not been investigated from a histochemi-
cal perspective previously.
In this study, we aimed to evaluate the relationship 
between glycemic control in patients with type 2 DM 




This study was designed as an observational, cross-sec-
tional and case–controlled study. Patients with type 2 
DM who presented to outpatient clinics of the Adnan 
Menderes University, Medical Faculty, Department of 
Endocrinology and Metabolic Disease between January 
and March 2012 were studied. The patients with type 
2 DM applying to the follow-up clinic, and lacking the 
exclusion criteria, agreeing to participate in the study 
were enrolled consecutively from January 2012. The 
study included 40 patients with type 2 DM with poor gly-
cemic control (HbA1c > 7), 30 patients with type 2 DM 
with good glycemic control (HbA1c  ≤  7) [14] and 31 
healthy controls. Patients with active infection, known 
malignancy, hematologic malignancy, iron deficiency, 
thrombotic conditions, renal transplantation, patients 
currently treated with cytotoxic agents, fenofibrate, and 
anti-inflammatory drugs, and pregnant women were 
excluded from the study.
Three peripheral blood smears (in fasting period) 
were analyzed for each patient included in the study. 
Myeloperoxidase dye was used for staining. Myelop-
eroxidase ratios in neutrophils (Fig.  1) were evaluated 
by one hematologist and one hematopathologist for 
proportions of staining with MPO in 100 neutrophils 
in each smear, and the mean value of the readings were 
reported [15].
Statistical analysis
SPSS 16.0 version was used for statistical analyses. Fit of 
the quantitative data to normal distribution was studied 
using the Shapiro–Wilk test. For variables that were fit for 
normal distribution, one-way variance analysis (ANOVA) 
was used for statistical comparisons and descriptive sta-
tistics were expressed as mean ±  standard deviation. For 
variables unfit for normal distribution, Kruskal–Wallis was 
used for statistical comparisons and descriptive statistics 
were expressed as median (25–75  ‰). The level of rela-
tionship between variables was studied with Spearman’s 
Rho correlation coefficient. Chi square test and Fisher test 
were used in analyzing categorical variables and descrip-
tive statistics were expressed as frequency (%). In our 
study, we used classification and regression tree (C&RT) 
method in order to choose the best predictor for MPO. 
p values < 0.05 were considered statistically significant.
Approval of the ethics board of the Medical Faculty of 
Adnan Menderes University was received.
Results
Type 2 DM patients with poor glycemic control 
had a mean age of 56.4  ±  9.99  years and type 2 DM 
patients with good glycemic control had a mean age of 
57.3 ± 10.02 years and healthy controls had a mean age of 
51.42 ± 11.48 years, with no significant difference among 
the groups (p > 0.05). Type 2 DM patients with poor gly-
cemic control had a disease duration of 12.3 ± 3.4 years 
and were not significantly different from type 2 DM 
patients with good glycemic control (p > 0.05). Myelop-
eroxidase ratio in neutrophils was 70 (58.5–80) in type 
2 DM patients with poor glycemic control compared to 
80 (73.75–90) in those with good glycemic control and 
88 (78–92) in healthy controls. The DM group with poor 
glycemic control was statistically significantly different 
from the other groups (p < 0.001). Good and poor con-
trolled diabetes groups were similar in terms of the drugs 
being used. No correlation was found between the MPO 
activity and the drugs used to treat diabetes (p  >  0.05). 
In patient groups with diabetes, statistically significant 
differences in terms of MPO activity was not detected 
among the patients using and not using sitagliptin, insu-
lin detemir, insulin glargine, insulin aspart, insulin lispro, 
insulin glulisine, metformin, gliclazide, repaglinide, nat-
eglinide, pioglitazone. Statistical results of quantitative 
and qualitative data are provided in Tables 1, 2, 3 and 4; 
Figs. 2 and 3 demonstrates correlation analysis between 
MPO and HbA1c.     
Fig. 1 Microscopic image of the neutrophil with positive MPO stain-
ing in peripheral blood
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We apllied the C&RT model in order to choose the best 
predictor for MPO development. In the model, patients 
were first divided into two branches according to their 
type 2 DM values (patients with poor glycemic control 
and good glycemic control and healthy controls) for the 
prediction of MPO. According to this model, type 2 DM 
patients with poor glycemic control had lower MPO 
activity in neutrophils (66.6 ±  21.6 versus 81.9 ±  14.0). 
MPO impact on the diagnosis of Type 2 DM was 100 % 
and the effects of drugs used to treat DM and HT was 
63 %.
Discussion
We determined histochemically that type 2 DM patients 
with poor glycemic control had lower MPO activity in 
neutrophils compared to both healthy controls and type 
2 DM patients with good glycemic control. Type 2 DM 
patients with good glycemic control and healthy controls 
did not differ significantly with respect to MPO activity 
in neutrophils.
Myeloperoxidase deficiency in neutrophils can be 
acquired or hereditary. Acquired MPO deficiency is 
rarer [10]. Hematologic malignancies, common cancers, 
cytotoxic agents, some antiinflammatory drugs, iron defi-
ciency, lead intoxication, thrombotic conditions, renal 
transplantation, serious infections, neuronal lipofusci-
nosis, pregnancy and DM have been shown among the 
causes of acquired MPO deficiency [8, 10]. Nita et  al. 
showed that fenofibrate reduced plasma MPO con-
centrations [16]. A study that compared MPO ratios in 
peripheral neutrophils in diabetic patients identified no 
significant difference in MPO ratios of diabetic patients 
with and without infection [11]. In the study by Sato 
et al. [12], decreased MPO activity was shown in leuko-
cytes of diabetic patients. Likewise, a study by Uchimura 
et al. [17] demonstrated markedly decreased MPO activ-
ity in leukocytes of patients with non-insulin dependent 
diabetes. On the other hand, Gorudko et  al. [13] found 
increased MPO activity in plasma of type 2 DM patients 
with no cardiovascular disease. In the study by Moldove-
anu et al. [18], patients with DM also had a higher MPO 
activity compared to the control group. In another study, 
serum MPO levels were found to be higher in overweight 
individuals who had first-degree relatives with type 2 
DM compared to the control group [19]. An animal 
study demonstrated that MPO expression was higher in 
Table 1 Comparison of laboratory findings between the three groups
a DM group with poor control is different from other groups
b It was used the Kruskal–Wallis test for statistical analysis
c It was used the ANOVA test for statistical analysis
d Control group is different from other groups
e All groups are different from each other
f DM group with poor control and DM group with good control are different from each other
g DM group with poor control and control group are different from each other
h Control group and DM group with good control are different from each other
DM with poor glycemic control DM with good glycemic control Controls p
MPO (%) 70 (58.5–80)a 80 (73.75–90) 88 (78–92) <0.001b
Hb (g/dL) 13.34 ± 1.63 13.52 ± 1.30 12.7 ± 1.47 >0.05c
Leukocyte (/mm3) 7961 ± 1624.48 7963.67 ± 1624.30 6608.71 ± 1411.78d 0.001c
Platelet (/mm3) 287375 ± 81599 280567 ± 72463 275968 ± 72470 >0.05c
HBA1C (%) 10.15 (8.8–13.85) 6.5 (5.98–6.8)e 5.4 (5–5.5) <0.001b
LDL (mg/dL) 124.48 ± 42.32 113.63 ± 27.40 127.39 ± 31.67 >0.05c
HDL (mg/dL) 39.85 ± 11.98f 46.73 ± 11.91 46.29 ± 10.19 0.019c
Triglyceride (mg/dL) 138.5 (110.75–192.75) 137.5 (103.5–209.25) 120 (87–190) >0.05b
Creatinine (mg/dL) 0.77 (0.72–0.93)a 0.72 (0.65–0.8) 0.73 (0.68–0.8) 0.021b
Fasting plasma glucose (mg/dL) 203.5 (156–304.5) 122 (97.75–128.25)e 90 (85–93) <0.001b
Postprandial plasma glucose (mg/dL) 298 (225–397.75) 147.5 (125.5–167.75)e 104 (95–120) <0.001b
Sedimentation (mm/h) 42.13 ± 22.27g 36.77 ± 18.31 26.48 ± 16.45 0.005c
C-reactive protein (g/dl) 3.41 (2.09–7.36)a 1.35 (0.7–3.85) 1.38 (0.94–3.63) 0.001b
Age 56.4 ± 9.99 57.3 ±10.02 51.42 ± 11.48 >0.05c
BMI (kg/m2) 29.45 (26.60–35.65) 27.88 (24.5–32.43) 25 (23.6–27.8)d 0.001b
MPV (fL) 9.4 (8.5–10.2) 8.4 (7.58–9.63) 8.9 (8.5–9.7) >0.05b
Hematocrite 39.35 (37.25–42.18) 40.6 (38.58–43.03) 36.7 (35.6–41.5)h 0.036b
24-h urine microalbuminuria (mg/day) 38 (16.25–88.25) 17 (12–29.25)e 12 (8–15) <0.001b
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diabetic neutrophils but reported decreased MPO activ-
ity in neutrophils compared to the control group [20].
The relationship between type 2 diabetes mellitus and 
MPO has been investigated by previous studies, which 
arrived at contradicting conclusions [13, 17–19]. There 
are a limited number of studies investigating the relation-
ship between glycemic response and MPO. The study by 
Sato et al. evaluating the effect of glycemic response on 
MPO demonstrated a significant correlation between 
decreased MPO activity in leukocytes and increased 
Table 2 Comparison of neuropathy presence and laboratory data in patients with type 2 DM
a The group with neuropathy and the control group are different from each other
b It was used the Kruskal–Wallis test for statistical analysis
c All groups are different from each other
d The group with neuropathy is different from other groups








MPO (%) 75 (50–86)a 80 (70–90) 87 (79.5–90.5) 0.011b
HBA1C (%) 9 (6.9–12.3)c 6.75 (5.6–9.75) 5.4 (5.08–5.5) <0.001b
Sedimentation (mm/h) 43.96 ± 21.89d 32.87 ± 20.16 31.05 ± 16.27 0.036e
C-reactive protein (g/dl) 4.1 (2.39–8.87)d 1.95 (0.83–3.88) 1.37 (0.93–4.45) 0.002b
Table 3 Comparison of nephropathy development and laboratory data in patients with type 2 DM
a Control group is different from other groups
b It was used the Kruskal–Wallis test for statistical analysis
c Control group and the group without nephropathy are different from each other
d It was used the ANOVA test for statistical analysis








MPO (%) 80 (70–85) 75 (54–88) 88 (78–92)a 0.003b
HBA1C (%) 9 (7.1–12) 6.9 (6.15–10.8) 5.4 (5–5.5)a <0.001b
Sedimentation (mm/h) 38 ± 21.25 40.39 ± 20.63 26.48 ± 16.45c 0.011d
C-reactive protein (g/dl) 3.44 (1.5–7.93) 2.41 (0.99–4.1) 1.38 (0.94–3.63)e 0.024b
Table 4 Comparison of complications presence in patients with type 2 DM
Fisher test were used in analyzing categorical variables and descriptive statistics were expressed as frequency (%)
a It was used the Chi square test for statistical analysis
Controls n (%) DM with poor control n (%) DM with good control n (%) Exact p
Sex Male 8 (25.8) 21 (52.5) 11 (36.7) >0.05a
Female 23 (74.2) 19 (47.5) 19 (63.3)
Neuropathy No 20 (50) 23 (76.7) <0.001a
Yes 20 (50) 7 (23.3)
CAD No 32 (80) 28 (93.3) <0.001a
Yes 8 (20) 2 (6.7)
Retinopathy No 31 (77.5) 28 (93.3) <0.001a
Yes 9 (22.5) 2 (6.7)
PAH No 38 (95) 29 (96.7) <0.001a
Yes 2 (5) 1 (3.3)
Diabetic foot No 38 (95) 30 (100) >0.05a
Yes 2 (5) 0 (0)
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HbA1c [12]. In our study, we also found a negative cor-
relation between Hba1C values and MPO levels.
Previous studies investigating the relationship between 
DM and MPO used the ELISA method [12, 13, 17–20]. 
With the literature scan, our study appears as the first to 
evaluate MPO activity in neutrophils in diabetic patients 
from a histochemical perspective. Histochemical evalu-
ation of MPO activities is cheaper and easier than sero-
logical methods.
Chronic hyperglycemia increases the release of reac-
tive oxygen species from neutrophils [21]. Neutrophil 
dysfunctions were shown as one of the causes of glyce-
mic unresponsiveness in diabetic patients. Abnormalities 
in granulocyte chemotaxis, phagocytosis and microbi-
cidal activities were described for patients with poorly-
controlled diabetes [22]. Impaired neutrophil bactericidal 
function was strongly associated with poor glycemic con-
trol and improved positively with good glycemic control 
[23]. The chronic hyperglycemia of poorly controlled dia-
betes can prime neutrophils and monocytes [24].
A positive correlation between HbA1c and white 
blood cell levels (WBC) in patients with type 2 DM was 
reported in a study [25]. Patients with type 2 DM are in 
a state of low-degree chronic inflammation that induces 
hypersecretion of inflammatory factors, which results in 
a constantly elevated neutrophilic granulocyte count [26]. 
In our study, WBC levels of DM groups with poor glyce-
mic control and good glycemic control were statistically 
significantly elevated from the control group (p < 0.001).
In a study, superoxide dismutase activity in the neutro-
phils of type 2 diabetes patients was decreased by 41  % 
compared to the control group. Glutathione peroxidase 
(GSHPx) and glutathione reductase (GR) activities of 
type 2 diabetic patients were 73.04 and 81.12 %, respec-
tively, compared to controls. No differences were noted 
in catalase activities. It has been suggested that these 
findings could account for some of the mechanisms that 
lead to increased sensitivity of type 2 DM patients to cer-
tain infections [27].
Increased glucose levels lead to increased protein glyca-
tion through early glycation products and advanced gly-
cation late products (AGE) in diabetic patients. This plays 
an important role in occurrence of complications [28]. 
In addition, AGE is one of the most important causes by 
which hyperglycemia causes cellular and tissue damage. 
Some AGEs occur on critical protein sites and may lead 
to enzymatic inactivation and loss of physiological func-
tion [29]. Thus, decreased MPO activity in patients with 
poorly controlled diabetes may be due to hyperglycemia-
associated negative modulation of the enzymatic activity 
[20].
This hypothesis was described for other enzymes previ-
ously. It suggests that the presence of high plasma glucose 
concentration might cause alterations in the molecular 
conformation of the enzyme or its catalytic site, possibly 
by glycation of amino acids [30].
There are varying opinions and results in the literature 
regarding the conditions that low MPO activity in neu-
trophils could lead to [31, 32]. Is MPO a friend or foe? 
[31]. It has been suggested that chronic inflammatory 
process and serious infections may be more frequent in 
patients with total or subtotal MPO deficiency [32]. Dif-
ferent publications have reported that serious infections 
as sporadic cases developed in less than 5 % of the indi-
viduals with MPO deficiency [8]. While it has been sug-
gested that there might be a relationship between MPO 
Fig. 2 Correlation between HbA1c and MPO in patients with DM
Fig. 3 Correlation between HbA1c and MPO in all groups
Page 6 of 7Unubol et al. Diabetol Metab Syndr  (2015) 7:119 
deficiency and cancer risk [8], a different publication has 
reported no increase in the incidence of cancer in indi-
viduals with MPO deficiency [31]. It has been suggested 
that MPO deficiency has cardioprotective effects [32].
Because this was a cross-sectional study, information 
on patients’ infections and malignancies were derived 
from patient reports. The relationship between MPO 
deficiency and infections or malignancies could not be 
evaluated as conclusive data could not be obtained. We 
believe that evaluation by prospective studies on the clin-
ical conditions that could be caused by MPO deficiency 
we observed in patients with poor glycemic control 
would be helpful.
There are several studies evaluating the relationship 
between MPO deficiency and atherosclerosis [33, 34]. 
In our study, a statistically significant difference was not 
noted in the MPO ratio between DM patients with and 
without neuropathy (p > 0.05). Also, no significant differ-
ence was observed between DM patients with and with-
out nephropathy with respect to MPO levels (p > 0.05). 
In our study, a statistical evaluation could not be per-
formed since the number of patients with coronary artery 
disease and diabetic rethinopathy in each group were 
insufficient. This was interpreted as a finding that differs 
from the findings of studies which demonstrated pro-
tective effects of deficient levels of MPO in neutrophils 
from atherosclerosis [33, 34]. The role of oxidative stress 
in development of diabetic microvascular complications 
is known [35] but poor glycemic control is the primary 
cause in development of the microvascular complications 
[36]. The study by Zhang demonstrated that MPO was 
not necessary to induce an experimental atherosclerosis 
model in MPO-deficiency-induced mice [37]. Our study 
indicates that microvascular complications in diabetic 
patients cannot be associated alone with MPO activ-
ity. Our study did not yield any finding which suggests 
that decreased MPO activity in neutrophils in diabetic 
patients prevented microvascular complications.
In conclusion, poor glycemic control in diabetic 
patients results in decreased MPO activity in neutro-
phils histochemically. We believe that variability in MPO 
activity by glycemic response in diabetic patients, com-
plications and their clinical relevance need to be assessed 
in prospective studies.
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